Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Actinium Pharmaceuticals, Inc.ATNM · Entity 7435 | Chief Medical Officer | September 01, 2021 | September 03, 2021 |
| Genprex, Inc.GNPX · Entity 8441 | Chief Medical Officer | February 27, 2026 | February 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Actinium Pharmaceuticals, Inc.
Report date September 01, 2021 · Filed September 03, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.07 · Expires 2031-09-01 | Direct | 67,164 |
Reported balance
After 2021-09-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-09-01 · Grant · Acquired 67,164 · Balance 67,164 F1: This price represents the closing price of the Company's common stock on the date of the board of directors approval of the grant. F2: Pursuant to the terms of the Company's Amended and Restated 2013 Stock Plan and 2019 Stock Plan, 2% of the options will vest each month from September 1, 2021 until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: This price represents the closing price of the Company's common stock on the date of the board of directors approval of the grant.
F2: Pursuant to the terms of the Company's Amended and Restated 2013 Stock Plan and 2019 Stock Plan, 2% of the options will vest each month from September 1, 2021 until fully vested.
Genprex, Inc.
Report date February 27, 2026 · Filed February 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,692 |
Reported balance
After 2026-02-27 transaction · row 1
1 source rowRow 1 · 2026-02-27 · Tax withholding · Disposed 7,168 · Balance 21,692 F1: Represents shares withheld on February 27, 2026 to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") previously granted under the Genprex, Inc. 2018 Equity Incentive Plan (as amended and restated effective June 30, 2025). |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld on February 27, 2026 to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") previously granted under the Genprex, Inc. 2018 Equity Incentive Plan (as amended and restated effective June 30, 2025).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2026 Filed Feb 27, 2026 23:34 UTC | Genprex, Inc. GNPX · Entity 8441 | Tax withholdingCommon Stock | 7,168 | $2.00 | $14,336.00 |
DisclosureSEC source: 0001437749-26-006154 · rdgdoc.xml · nonDerivative · entry 1 Berger Mark Stanley · CIK 0001700283 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,692 F1 · shares: Represents shares withheld on February 27, 2026 to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") previously granted under the Genprex, Inc. 2018 Equity Incentive Plan (as amended and restated effective June 30, 2025). Read SEC document |
| December 22, 2025 Filed Dec 23, 2025 22:35 UTC | Genprex, Inc. GNPX · Entity 8441 | GrantCommon Stock | 28,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-038735 · rdgdoc.xml · nonDerivative · entry 1 Berger Mark Stanley · CIK 0001700283 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,860 F1 · shares: This award of Restricted Stock Units ("RSUs") is granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan (as amended and restated effective June 30, 2025, the "EIP") and vests in installments of 50% on February 27, 2026 and the remaining 50% on February 27, 2027, provided that the recipient continues to serve as a Service Provider (as defined in the Company's EIP) through the applicable vesting dates. Vested RSUs will be paid in shares of the Company's common stock, $0.001 par value, on a one-to-one basis. F2 · balance_after: This total represents the number of shares of Common Stock beneficially owned following this reported transaction and the 1-for-50 reverse stock split of the Company's Common Stock effected as of October 21, 2025. Read SEC document |
| June 30, 2025 Filed Jul 1, 2025 21:52 UTC | Genprex, Inc. GNPX · Entity 8441 | Tax withholdingCommon Stock | 4,500 | $0.23 | $1,025.55 |
DisclosureSEC source: 0001437749-25-021819 · rdgdoc.xml · nonDerivative · entry 1 Berger Mark Stanley · CIK 0001700283 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,971 F1 · shares: Represents shares withheld on June 30, 2025 to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") previously granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 01:01 UTC | Genprex, Inc. GNPX · Entity 8441 | Tax withholdingCommon Stock | 585 | $0.41 | $239.85 |
DisclosureSEC source: 0001437749-25-004466 · rdgdoc.xml · nonDerivative · entry 1 Berger Mark Stanley · CIK 0001700283 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,471 F1 · shares: Represents shares withheld on February 18, 2025 to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") previously granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan. Read SEC document |
| December 05, 2024 Filed Dec 6, 2024 22:48 UTC | Genprex, Inc. GNPX · Entity 8441 | GrantCommon Stock | 18,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-036878 · rdgdoc.xml · nonDerivative · entry 1 Berger Mark Stanley · CIK 0001700283 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,056 F1 · shares: This award of Restricted Stock Units ("RSUs") is granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan and vests 100% as of June 30, 2025, provided that the recipient continues to serve as a Service Provider (as defined in the Company's 2018 Equity Incentive Plan) through the applicable vesting date. Vested RSUs will be paid in shares of the Company's common stock, $0.001 par value, on a one-to-one basis. Read SEC document |
| February 18, 2024 Filed Feb 21, 2024 21:34 UTC | Genprex, Inc. GNPX · Entity 8441 | Tax withholdingCommon Stock | 1,319 | $4.40 | $5,803.60 |
DisclosureSEC source: 0001437749-24-005062 · rdgdoc.xml · nonDerivative · entry 1 Berger Mark Stanley · CIK 0001700283 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,806 F1 · shares: Represents shares withheld on February 18, 2024 to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") previously granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan. F2 · balance_after: This total represents the number of shares of Common Stock beneficially owned following this reported transaction and the 1-for-40 reverse stock split of the Company's Common Stock effected as of February 2, 2024. Read SEC document |
| February 18, 2023 Filed Feb 22, 2023 23:35 UTC | Genprex, Inc. GNPX · Entity 8441 | GrantCommon Stock | 245,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-004241 · rdgdoc.xml · nonDerivative · entry 1 Berger Mark Stanley · CIK 0001700283 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,000 F1 · shares: This award of Restricted Stock Units ("RSUs") is granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan and vests in installments of 50% on the first anniversary of the date of grant and the remaining 50% on the second anniversary of the date of grant. Vested RSUs will be paid in shares of the Company's common stock, $0.001 par value, on a one-to-one basis. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 21:32 UTC | Genprex, Inc. GNPX · Entity 8441 | GrantStock Option (right to buy) · Derivative | 98,750 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0001437749-22-002744 · rdgdoc.xml · derivative · entry 1 Berger Mark Stanley · CIK 0001700283 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,750 Underlying: Common Stock · 98,750 shares Expires 2032-02-04 F1 · derivative.exercise_date: The option (the "Option") was granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan (the "Plan"). The Option shall vest and become exercisable as to one third (1/3) of the total number of shares (the "Shares") of the Company's common stock, $.001 par value subject to the Option on February 4, 2023 (the "Vesting Commencement Date") and thereafter shall vest and become exercisable as to an additional 1/24 of the remaining Shares subject to the Option on each monthly anniversary of the Vesting Commencement Date until fully vested and exercisable, in each case provided that the Optionee continues to serve as a Service Provider (as defined in the Plan) through the applicable vesting date. Read SEC document |
| September 27, 2021 Filed Sep 28, 2021 20:26 UTC | Genprex, Inc. GNPX · Entity 8441 | GrantStock Option (right to buy) · Derivative | 550,000 | $0.00 Strike: $2.85 | $0.00 |
DisclosureSEC source: 0001437749-21-022776 · rdgdoc.xml · derivative · entry 1 Berger Mark Stanley · CIK 0001700283 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,000 Underlying: Common Stock · 550,000 shares Expires 2031-09-27 F1 · security: The options were granted outside of the Registrant's incentive award plans as an inducement grant pursuant to Nasdaq Listing Rule 5635(c)(4). F2 · derivative.exercise_date: One-third of the options will vest on each of the first, second and third anniversaries of the date on which the Reporting Person commences employment with the Registrant. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:04 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantStock Option (Right to Buy) · Derivative | 67,164 | $0.00 Strike: $6.07 | $0.00 |
DisclosureSEC source: 0001213900-21-046687 · ownership.xml · derivative · entry 1 Berger Mark Stanley · CIK 0001700283 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,164 Underlying: Common Stock · 67,164 shares Expires 2031-09-01 F1 · derivative.exercise_price: This price represents the closing price of the Company's common stock on the date of the board of directors approval of the grant. F2 · derivative.exercise_date: Pursuant to the terms of the Company's Amended and Restated 2013 Stock Plan and 2019 Stock Plan, 2% of the options will vest each month from September 1, 2021 until fully vested. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 21:17 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantStock Option (Right to Buy) · Derivative | 46,667 | $0.00 Strike: $9.55 | $0.00 |
DisclosureSEC source: 0001213900-20-022337 · ownership.xml · derivative · entry 1 Berger Mark Stanley · CIK 0001700283 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,667 Underlying: Common Stock · 46,667 shares Expires 2030-08-12 F1 · derivative.exercise_price: This price represents the closing price of the Company's common stock on the date of the board of directors approval of the grant. F2 · derivative.exercise_date: Pursuant to the terms of the Company's Amended and Restated 2013 Stock Plan and 2019 Stock Plan, 2% of the options will vest each month from August 12, 2020 until fully vested. Read SEC document |
| July 12, 2019 Filed Jul 16, 2019 21:07 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantOptions to purchase common stock · Derivative | 400,000 | $0.23 Strike: $0.23 | $92,800.00 |
DisclosureSEC source: 0001213900-19-012879 · ownership.xml · derivative · entry 1 Berger Mark Stanley · CIK 0001700283 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2029-07-12 F1 · derivative.exercise_date: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options vest each month from the date of grant. Read SEC document |
| March 05, 2019 Filed Mar 7, 2019 21:15 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | OtherCommon Stock | 3,500 | $0.60 | $2,100.00 |
DisclosureSEC source: 0001213900-19-003738 · ownership.xml · nonDerivative · entry 1 Berger Mark Stanley · CIK 0001700283 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Read SEC document |
| July 13, 2018 Filed Jul 17, 2018 21:15 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantOptions to purchase common stock · Derivative | 250,000 | $0.78 Strike: $0.78 | $195,725.00 |
DisclosureSEC source: 0001213900-18-009320 · ownership.xml · derivative · entry 1 Berger Mark Stanley · CIK 0001700283 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2028-07-13 F1 · derivative.exercise_date: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options vest each month from the date of grant. Read SEC document |
| March 06, 2018 Filed Mar 19, 2018 21:04 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | OtherSeries B Warrants · Derivative | 10,500 | $0.50 Strike: $0.70 | $5,250.00 |
DisclosureSEC source: 0001213900-18-003155 · f4030618berger_actinium.xml · derivative · entry 3 Berger Mark Stanley · CIK 0001700283 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 10,500 shares Expires 2020-09-06 Read SEC document |
| March 06, 2018 Filed Mar 19, 2018 21:04 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | OtherSeries A Warrants · Derivative | 3,500 | $0.50 Strike: $0.60 | $1,750.00 |
DisclosureSEC source: 0001213900-18-003155 · f4030618berger_actinium.xml · derivative · entry 2 Berger Mark Stanley · CIK 0001700283 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Underlying: Common Stock · 3,500 shares Expires 2019-03-06 Read SEC document |
| March 06, 2018 Filed Mar 19, 2018 21:04 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | OtherCommon Stock | 14,000 | $0.50 | $7,000.00 |
DisclosureSEC source: 0001213900-18-003155 · f4030618berger_actinium.xml · nonDerivative · entry 1 Berger Mark Stanley · CIK 0001700283 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Read SEC document |
| June 15, 2017 Filed Jun 15, 2017 20:56 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | PurchaseCommon stock | 5,000 | $1.11 | $5,550.00 |
DisclosureSEC source: 0001213900-17-006531 · f4061517berger_actinium.xml · nonDerivative · entry 1 Berger Mark Stanley · CIK 0001700283 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.